It’s a good year so far for healthcare up-starts. The organizations – with concentrations varying from biotechs making cutting-edge devices to harnessing plant microbiomes have earned a sum of $15 billion in fundraising. That is the highest amount of money funded in the initial half of the year throughout the past ten years. Some of the UK as well as with the US-based firms have obtained unicorn standing, others have improved their already billion-dollar appraisals. Amidst the companies that have added to the prosperous beginning half of 2018 are headliners like 23andMe, most recognized for its genetics tests that let their clients know (almost) everything they want to understand about their genome.
HumanLongevity, which provides its clients with a total physical examination that they believe will find anything that could be health-compromising, helping patients live more fuller lives. Lastly, BenevolentAI which utilized artificial intelligence to find out treatments for hard-to-diagnose diseases like Parkinson’s and uncommon cancers. On the highest of the list, still, is Eric Lefkofsky’s Tempus, a technology company based out of Chicago that is creating the planet’s largest archive of molecular and clinical patient data and an execution system that lets physicians easily access their library.
According to the founder and CEO, Lefkofsky, the aim is on data-driven precision treatment. This targeted medicine outlook has started to revolutionize the way cancer medicine is treated by the people offering care. Lefkofsky created Tempus in 2015. Throughout the past three years, it has earned the title of one of Chicago’s best ten health tech organizations and it has also earned unicorn status following just a couple of years. Tempus currently funded $80 million during March, bringing its cumulative funding to upwards of $210 million. “Our aim at Tempus is to enhance patient results and one of the best ways to do so is by empowering physicians and researchers with information that can expedite research and promote patient care,” stated Lefkofsky.